US Bancorp DE Sells 1,380 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

US Bancorp DE decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 53.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,209 shares of the company’s stock after selling 1,380 shares during the quarter. US Bancorp DE’s holdings in CRISPR Therapeutics were worth $48,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Boston Family Office LLC grew its stake in shares of CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock worth $459,000 after acquiring an additional 213 shares during the last quarter. Bedell Frazier Investment Counselling LLC grew its stake in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after acquiring an additional 218 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after acquiring an additional 231 shares during the last quarter. Sunbelt Securities Inc. grew its stake in shares of CRISPR Therapeutics by 11.3% in the third quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock worth $139,000 after acquiring an additional 300 shares during the last quarter. Finally, Kestra Private Wealth Services LLC grew its stake in shares of CRISPR Therapeutics by 1.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock worth $812,000 after acquiring an additional 310 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Bank of America cut their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. The Goldman Sachs Group dropped their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Stifel Nicolaus dropped their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Finally, Truist Financial increased their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $73.11.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares in the company, valued at $3,288,822.60. This trade represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 over the last quarter. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $40.97 on Wednesday. The business’s 50-day moving average is $43.04 and its two-hundred day moving average is $45.47. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $75.91. The company has a market cap of $3.51 billion, a price-to-earnings ratio of -9.38 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.